The Memo: Medulla Pro Guiding the Next Generation of Needle-Based Procedures

Under the direction of CEO Boyle Suwono, Medulla Pro is reimagining how clinicians perform some of the most common — but error-prone — procedures in medicine. From lumbar punctures to nerve blocks, the company is building intuitive, real-time ultrasound guidance systems designed to boost precision, improve outcomes, and reduce procedural complications for patients and providers alike.

“We’re giving doctors clarity and confidence — even in the most challenging cases,” Boyle said.

Headquartered in Singapore, Medulla Pro is preparing to launch two products: one for lumbar punctures and one for peripheral nerve blocks. With clinical trials on the horizon, the company is moving fast — and aiming to make a meaningful difference in how care is delivered across a wide range of specialties.

Origin Story

Medulla Pro was born out of a real-world problem. In 2018, a Singapore-based hematologist struggled to perform a lumbar puncture on a cancer patient struggling with obesity — ultimately traumatizing the patient and jeopardizing his treatment.

“This doctor needed to deliver chemotherapy via lumbar puncture due to the type of cancer but couldn’t safely access the cerebrospinal fluid after multiple attempts,” Boyle explained. “That failure led to the patient refusing the procedure entirely.”

The physician brought the problem to Trendlines, an Israeli-Singaporean medtech incubator, which helped design the early technology. In 2024, Boyle — a former startup executive with engineering roots and a background in dental 3D printing — joined as CEO.

“I realized I wasn’t as interested in the printing technology — I was interested in the healthcare impact,” Boyle said. “When I came across Medulla Pro, it checked every box: meaningful clinical need, smart engineering, and the chance to help patients.”


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-medulla-pro-guiding-the-next-generation-of-needle-based-procedures 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more